| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg | |||
| 50mg | |||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Betamethasone acetate targets the glucocorticoid receptor. As a corticosteroid, it binds to the glucocorticoid receptor and modulates gene expression, leading to anti-inflammatory and immunosuppressive effects. It is a prodrug that is converted to the active form, betamethasone.
|
|---|---|
| ln Vitro |
In vitro, Betamethasone acetate is a glucocorticoid corticosteroid. It binds to the glucocorticoid receptor and modulates gene expression. It is a prodrug with low aqueous solubility. Detailed in vitro activity data including receptor binding affinity and anti-inflammatory potency are available in the primary literature.
|
| ln Vivo |
In vivo, Betamethasone acetate induces fetal lung maturation in preterm sheep. It is used as a corticosteroid for its anti-inflammatory and immunosuppressive effects. It is a prodrug that is converted to the active form, betamethasone. It is used in clinical settings for various inflammatory conditions.
|
| Enzyme Assay |
In vitro receptor binding assays for Betamethasone acetate typically involve evaluating its affinity for the glucocorticoid receptor using competitive radioligand binding. Membrane preparations or cytosolic fractions from cells expressing the receptor are incubated with radiolabeled dexamethasone and varying concentrations of the compound. IC50 or Ki values are calculated from displacement curves.
|
| Cell Assay |
Cell-based assays for Betamethasone acetate involve culturing cells expressing the glucocorticoid receptor. Cells are treated with Betamethasone acetate at concentrations ranging from 0.1 nM to 10 µM. Receptor activation is measured by reporter gene assays or by measuring the expression of glucocorticoid-responsive genes. Anti-inflammatory activity is assessed by measuring cytokine production.
|
| Animal Protocol |
In vivo animal experiments for Betamethasone acetate typically involve administration to animal models via injection or oral administration. Anti-inflammatory effects are assessed in models of inflammation. Fetal lung maturation is evaluated in preterm animal models. Pharmacokinetic parameters are evaluated by measuring compound and metabolite levels in blood and tissues. Toxicity is assessed by monitoring clinical parameters.
|
| ADME/Pharmacokinetics |
Betamethasone acetate (molecular weight 434.5, formula C24H31FO6) is a synthetic corticosteroid prodrug. It is practically insoluble in water, freely soluble in acetone, and soluble in ethanol and methylene chloride. It has a melting point of 200-220°C (dec.). It is converted to the active form betamethasone.
|
| Toxicity/Toxicokinetics |
Betamethasone acetate is generally well-tolerated when used as prescribed. Common side effects of corticosteroids include immunosuppression, hyperglycemia, osteoporosis, and Cushing's syndrome. Comprehensive toxicological evaluation has been conducted for regulatory approval. It is a prescription medication and should be used under medical supervision.
|
| References |
: Ehling S, Baynes RE, Bäumer W. Impact of synthetic canine cerumen on in vitro penetration of auricular skin of dogs by florfenicol, terbinafine, and betamethasone acetate. Am J Vet Res. 2018 Mar;79(3):333-341. doi: 10.2460/ajvr.79.3.333.
|
| Additional Infomation |
Dexamethasone acetate is a corticosteroid. Dexamethasone acetate, commonly known as dexamethasone, is a glucocorticoid that was once marketed in the United States for the treatment of inflammatory respiratory diseases, allergic diseases, autoimmune diseases, and other conditions. Developed in 1957, dexamethasone has a structure similar to other corticosteroids such as hydrocortisone and prednisolone. While dexamethasone acetate has been largely superseded by dexamethasone phosphate, it continues to be used to treat various inflammatory diseases. Recently, dexamethasone has received significant attention in the treatment of COVID-19. A press release issued on June 16, 2020, highlighted early results from a clinical trial called "Randomized Evaluation of COVID-19 Treatment" (RECOVERY), which reported that dexamethasone reduced mortality by approximately one-fifth and one-third in COVID-19 patients receiving oxygen therapy and mechanical ventilation, respectively. Therefore, dexamethasone has been recommended as a life-saving drug for treating COVID-19 patients with severe respiratory symptoms.
Betamethasone acetate (CAS#: 987-24-6) is a synthetic glucocorticoid corticosteroid and the 21-acetate ester of betamethasone. It is a prodrug with low aqueous solubility. It induces fetal lung maturation in preterm sheep. Molecular weight: 434.5, formula: C24H31FO6. |
| Molecular Formula |
C24H31FO6
|
|---|---|
| Molecular Weight |
434.5044
|
| Exact Mass |
434.21
|
| CAS # |
987-24-6
|
| Related CAS # |
Betamethasone;378-44-9;Betamethasone disodium phosphate;151-73-5;Betamethasone hydrochloride;956901-32-9;Betamethasone acetate-d5
|
| PubChem CID |
236702
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
579.4±50.0 °C at 760 mmHg
|
| Melting Point |
200-220°C (dec.)
|
| Flash Point |
304.2±30.1 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.571
|
| LogP |
2.96
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
910
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@H](C[C@]2(C)[C@]1(C(=O)COC(=O)C)O)O)F
|
| InChi Key |
AKUJBENLRBOFTD-QZIXMDIESA-N
|
| InChi Code |
InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17-,18-,19-,21-,22-,23-,24-/m0/s1
|
| Chemical Name |
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-acetate
|
| Synonyms |
Betamethasone 21-acetateBetamethasone acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3015 mL | 11.5075 mL | 23.0150 mL | |
| 5 mM | 0.4603 mL | 2.3015 mL | 4.6030 mL | |
| 10 mM | 0.2301 mL | 1.1507 mL | 2.3015 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA